Core Insights - The "Masitide Peptide Dreams Series Research Results Seminar" was held in Beijing, announcing that two key Phase III clinical studies of the innovative weight-loss and blood-sugar-lowering drug Masitide Peptide were published in the prestigious journal "Nature" on December 18, 2025, marking the first Phase III clinical studies from China in the field of metabolic diseases published in this journal [1][3]. Group 1: Drug Development and Approval - Masitide Peptide is developed by Innovent Biologics and was approved for market release by the National Medical Products Administration on June 24, 2025 [3]. - In 2025, a total of 76 innovative drugs were approved for market, with 65 being domestically developed, accounting for over 85% of the total [3]. Group 2: Clinical Research Findings - The two studies published in "Nature" include DREAMS-1, focusing on monotherapy in type 2 diabetes patients, and DREAMS-2, examining the drug's use in conjunction with oral hypoglycemic agents, both based on data from Chinese patients [3]. - Results indicate that Masitide Peptide significantly outperformed control treatments in blood sugar control and weight management, showing comprehensive improvement in various cardiovascular, metabolic, liver, and kidney-related indicators [3][4]. Group 3: Clinical Implications - The current trend in treating type 2 diabetes in China shows an increasing patient base with earlier onset and rising rates of overweight and obesity, necessitating treatment strategies that effectively control blood sugar while also addressing weight and metabolic risks [3]. - The DREAMS series studies provide high-quality evidence for the shift towards comprehensive management of multiple metabolic risks rather than solely focusing on blood sugar control [4].
玛仕度肽两篇临床研究成果登顶《自然》主刊